Kura Oncology (KURA) Research & Development (2014 - 2026)
Kura Oncology (KURA) posted quarterly Research & Development of $65.3 million for Q1 2026, up 16.6% year-over-year from $56.0 million in Q1 2025, and up 16.6% quarter-over-quarter from $56.0 million in Q1 2025.
Kura Oncology (KURA) Research & Development (2014 - 2026) Analysis & Trends
Kura Oncology (KURA) has reported Research & Development for 11 consecutive years, with $65.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development rose 16.6% year-over-year to $65.3 million; the TTM figure through Mar 2026 stood at $215.2 million (up 13.46% YoY), while the FY2025 annual figure was $251.1 million, up 47.72% from the prior year.
- Research & Development improved to $65.3 million in Q1 2026 per KURA's latest filing, from $56.0 million in the prior quarter.
- Across five years, Research & Development topped out at $65.3 million in Q1 2026 and bottomed at $20.9 million in Q1 2022.
- Historically, Research & Development has averaged $35.7 million across 5 years, with a median of $30.9 million in 2023.
- Annual changes were most pronounced in 2022 — Research & Development climbed 2.9% — and 2024, when it jumped 60.66%.
- Kura Oncology's Research & Development stood at $22.7 million in 2022, then surged by 43.52% to $32.5 million in 2023, then surged by 60.66% to $52.3 million in 2024, then climbed by 7.09% to $56.0 million in 2025, then advanced by 16.6% to $65.3 million in 2026.
- Business Quant data shows KURA's Research & Development at $65.3 million in Q1 2026, $56.0 million in Q1 2025, and $52.3 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Kura Oncology | 966.11 Mn | 966.11 Mn | 20.63 Mn | 61.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 61.89 Mn |
| Mar 31, 2026 | 65.26 Mn |
| Mar 31, 2025 | 55.97 Mn |
| Dec 31, 2024 | 52.27 Mn |
| Sep 30, 2024 | 41.71 Mn |
| Jun 30, 2024 | 39.73 Mn |
| Mar 31, 2024 | 36.27 Mn |
| Dec 31, 2023 | 32.53 Mn |
| Sep 30, 2023 | 29.33 Mn |
| Jun 30, 2023 | 28.18 Mn |
| Mar 31, 2023 | 25.19 Mn |
| Dec 31, 2022 | 22.67 Mn |
| Sep 30, 2022 | 24.97 Mn |
| Jun 30, 2022 | 24.26 Mn |
| Mar 31, 2022 | 20.91 Mn |
| Dec 31, 2021 | 20.96 Mn |
| Sep 30, 2021 | 22.37 Mn |
| Jun 30, 2021 | 21.07 Mn |
| Mar 31, 2021 | 20.32 Mn |
| Dec 31, 2020 | 17.52 Mn |